Alnylam Pharmaceuticals
ALNY
#443
Rank
C$72.97 B
Marketcap
C$552.36
Share price
1.06%
Change (1 day)
60.55%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): C$0.16

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$0.12. In 2023 the company made an earnings per share (EPS) of C-$4.87 an increase over its 2022 EPS that were of C-$12.82.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$0.16
2023C-$4.87-62%
2022C-$12.8229.03%
2021C-$9.94-3.36%
2020C-$10.28-8.48%
2019C-$11.237.67%
2018C-$10.4339.74%
2017C-$7.4712.94%
2016C-$6.6138.84%
2015C-$4.76-32.88%
2014C-$7.09259.44%
2013C-$1.97-31.25%
2012C-$2.87

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
C-$1.73-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
C$59.95 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$3.78-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.33-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.01-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
C$10.16 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$5.11 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
C$0.87 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel